How Long Can I Stay on Hormone Replacement Therapy? By Dr. Michele Couri, MD, FACOG, ABIHM

How Long Can I Stay on Hormone Replacement Therapy?

By Dr. Michele Couri, MD, FACOG, ABIHM

One of the most common questions I receive from patients is, “How long can I safely stay on hormone replacement therapy (HRT)?” For years, women were told to use HRT for as little time as possible, often no more than five years. Thankfully, scientific understanding has evolved—and today’s evidence offers a much more logical and reassuring answer. Long before the science caught up, some of my wisest mentors in OB/GYN understood the profound value of staying on HRT long term. They knew that when used appropriately, HRT could preserve health, vitality, and quality of life well beyond menopause. It’s gratifying to see modern data now affirm what they understood through decades of clinical wisdom.   

There Is No Arbitrary Time Limit on HRT

Current guidance from The Menopause Society (formerly the North American Menopause Society) affirms that there is no fixed time limit for staying on HRT. Decisions about continuation should be individualized, taking into account a woman’s symptoms, risk factors, age, and personal preferences [1].

For many women who start hormone therapy around the time of menopause, the benefits are profound—and in many cases, continuing therapy long-term is both appropriate and health-promoting.

Cardiovascular Benefits: Timing Matters

Estrogen is protective for the heart and blood vessels when started early—ideally within 10 years of menopause or before age 60. In the ELITE trial, women who initiated estradiol early had significantly slower progression of atherosclerosis (blood vessel plaque) compared to those who started later [2].

Additionally, a reanalysis of the Women’s Health Initiative (WHI) data showed that women aged 50–59 who started estrogen therapy had a 33% reduction in coronary heart disease and lower overall mortality [3].

Stronger Bones, Fewer Fractures

Estrogen is essential for maintaining bone density and preventing osteoporosis. Postmenopausal women not on HRT can lose up to 20% of their bone mass within 5–7 years of menopause. HRT has been shown to reduce the risk of spine and hip fractures by up to 35% [4].

Importantly, HRT does more than prevent bone loss—it can increase bone mineral density (BMD) as well. Studies show that:

• Lumbar spine BMD increases by approximately 4–5% within the first year of HRT use [5,6].
• Hip BMD increases by about 1–2% per year, depending on the formulation and dose [5].

Furthermore, Dr. Gino Tutera, whom I learned a great deal from, was a pioneer in bioidentical hormone replacement therapy and founder of the SottoPelle® method.  He reported that hormone pellet therapy could increase bone density by approximately 8.3% per year, which is significantly higher than the increases seen with oral or transdermal HRT [15].

HRT is considered a first-line option for osteoporosis prevention in women under 60 or within 10 years of menopause who are also experiencing menopausal symptoms [1].

Cognitive Protection: The “Critical Window”

Evidence suggests that starting HRT early may be neuroprotective. The Cache County Study reported that women who began HRT near the onset of menopause had a significantly reduced risk of developing Alzheimer’s disease [7].

Brain imaging research by Dr. Lisa Mosconi also demonstrates that estrogen helps maintain brain glucose metabolism and structural integrity—particularly when started during the “critical window” within a decade of menopause [8].

Mental Health: Improvements in Mood, Depression, and Anxiety

Mood changes, anxiety, and depressive symptoms are common during the menopause transition—and HRT may help significantly. A meta-analysis published in JAMA Psychiatry found that estrogen-based therapy reduced depressive symptoms in perimenopausal and early postmenopausal women [9].

A 2021 review in Menopause showed that women on HRT reported improved overall well-being, decreased anxiety, and improved sleep quality, all of which contribute to better mental health [10].

Estrogen is also known to enhance serotonin and dopamine activity—neurotransmitters that play a major role in mood regulation.

Anti-Inflammatory Effects of Estrogen and Reduction in Joint Pain

Estrogen plays a significant role in modulating inflammation and maintaining musculoskeletal health. Its decline during menopause is associated with increased joint pain and stiffness. Estrogen helps regulate inflammatory responses by decreasing the production of pro-inflammatory cytokines such as IL-6 and TNF-α, thereby reducing inflammation in joints and connective tissues [16].

Dr. Vonda Wright, an orthopedic surgeon and researcher, has described a collection of musculoskeletal symptoms experienced during menopause as the “musculoskeletal syndrome of menopause.” This syndrome includes joint pain (arthralgia), loss of muscle mass, decreased bone density, and progression of osteoarthritis, largely influenced by estrogen fluctuations [17].

Clinical studies have indicated that estrogen supplementation can reduce the frequency of joint pain among postmenopausal women. Estrogen therapy has been shown to alleviate symptoms of osteoarthritis and improve joint function by reducing inflammation and preserving cartilage health [18].

What About Breast Cancer Risk? The Data Reassures

Dr. Avrum Bluming, a hematologist/oncologist and breast cancer researcher, has helped lead a reassessment of the perceived breast cancer risks of HRT. In Estrogen Matters, coauthored with Dr. Carol Tavris, he highlights key findings:

• Estrogen-alone therapy in women with hysterectomy actually reduced breast cancer incidence and mortality in the WHI [13].
• The small increased risk seen with combined therapy (estrogen + medroxyprogesterone acetate) may not apply to bioidentical hormones, and even then, the absolute risk increase was extremely small.
• European studies, such as the E3N Cohort, show that micronized progesterone (Prometrium®) with estrogen is associated with a safer breast profile than synthetic progestins [14].

Vaginal Estrogen: Small Dose, Big Impact

Even women on systemic HRT may benefit from adding vaginal estrogen for local relief of genitourinary syndrome of menopause (GSM), including vaginal dryness, burning, urinary urgency, and painful intercourse.

Importantly, vaginal estrogen has been shown to reduce the risk of recurrent urinary tract infections (UTIs) by 50%. In a randomized controlled trial, women using vaginal estrogen experienced significantly fewer UTIs over a 12-month period compared to placebo [11].

New 2025 AUA Guidelines Support Safety in Breast Cancer Survivors

The 2025 American Urological Association (AUA) guidelines, developed with the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) and the American Urogynecologic Society (AUGS), provide updated recommendations on the management of GSM. Notably, they state:

• Low-dose vaginal estrogen does not increase the risk of breast cancer recurrence, cardiovascular disease, dementia, or endometrial cancer.
• Women with a history of breast cancer can use low-dose vaginal estrogen safely, following a shared decision-making process [12].
• In women who are on systemic estrogen therapy but who still have symptoms of genitourinary syndrome of menopause, it is recommended to start vaginal estrogen therapy.  

These guidelines reflect a significant shift toward individualized care, empowering more women to benefit from this therapy safely.

The Bottom Line

Hormone therapy is not a temporary “band-aid”—for many women, it’s a long-term investment in health and vitality. It relieves symptoms, protects the heart and bones, supports the brain and mood, and improves vaginal and urinary health. Most importantly, it can be continued safely for as long as the benefits outweigh the risks for each individual woman.

If you’re doing well on HRT, there’s often no reason to stop.

To Your Health,

Dr. Couri

DISCLAIMER: The information provided on this website is intended for general informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. The information provided is current as of the date of publication or last review, but medical knowledge is constantly evolving, and the information may become outdated over time.

References

1. The Menopause Society 2022 Hormone Therapy Position Statement. Menopause. 2022;29(7):767–794.
2. Hodis HN et al. Vascular Effects of Early vs Late Postmenopausal Treatment with Estradiol. NEJM. 2016;374:1221–1231.
3. Manson JE et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality. JAMA. 2017;318(10):927–938.
4. Gallagher JC. Effect of Early Menopause on Bone Mineral Density. Menopause. 2007;14(3 Pt 2):567–571.
5. Recker RR et al. Effects of estrogen replacement therapy on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 1999;84(2):464–468.
6. Lindsay R et al. Prevention of spinal osteoporosis in oophorectomized women. Lancet. 1980;2(8197):1151–1154.
7. Zandi PP et al. Hormone Replacement Therapy and Alzheimer Disease. JAMA. 2002;288(17):2123–2129.
8. Mosconi L et al. Sex Differences in Alzheimer’s Risk. Neurology. 2017;89(13):1382–1390.
9. Gordon JL et al. Efficacy of Hormone Therapy on Depressive Symptoms in Perimenopausal and Postmenopausal Women: A Meta-analysis. JAMA Psychiatry. 2020;77(4):361–369.
10. Freeman EW. Effects of Hormone Therapy on Mood in Menopausal Women. Menopause. 2021;28(3):320–329.
11. Perrotta C et al. Oestrogens for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women. Cochrane Database Syst Rev. 2008;(2).
12. Kaufman MR, Ackerman LA, Amin KA, et al. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. J Urol. 2025.
13. Chlebowski RT et al. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone. JAMA. 2010;304(15):1684–1692.
14. Fournier A et al. Breast Cancer Risk and Hormone Therapy: The E3N Cohort Study. Int J Cancer. 2005;114(3):448–454.
15. Brannon, Dr. The Hormone Handbook. Optimal Bio. Available at: https://optimalbio.com/wp-content/uploads/2023/05/Dr.-Brannons-The-Hormone-Handbook.pdf
16. Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28(5):521–574.
17. Wright V. Fitness After 40: Your Strong Body at 40, 50, 60, and Beyond. AMACOM Books; 2007.
18. Szoeke C et al. The effects of menopausal hormone therapy on bone, muscle and joint health. Climacteric. 2017;20(4):303–309.